论文部分内容阅读
1991年,Schmidt-wolf等在外周血淋巴细胞(PBLn)中首次发现d0天加入IFN—r,d1天加入IL-1、IL-2、CD3mAb,此后定期补充IL-2,经2-4周的培养可收获大量肿瘤杀伤细胞,将其命名为C I K细胞。其中包括CD3+CD56+细胞、CD3+CD56+-、CD56+细胞,而CD3+CD56+细胞在其中起主要杀伤作用,CD3+CD56+细胞占CIK中的50%以上,绝对值较诱导前扩增1000-6000倍。CIK细胞又称自然杀伤样T淋巴细胞,具有NK细胞的非主要组织相容
In 1991, Schmidt-wolf et al. First found that adding IFN-r on day 0 in PBLn, adding IL-1, IL-2 and CD3 mAb on day d and thereafter regularly supplementing IL-2 for 2-4 weeks The culture can harvest a large number of tumor killer cells, named CIK cells. Including CD3 + CD56 + cells, CD3 + CD56 + -, CD56 + cells, and CD3 + CD56 + cells play a major role in killing them. CD3 + CD56 + cells account for more than 50% of CIKs, with an absolute value of 1000-6000 times . CIK cells, also known as natural killer-like T lymphocytes, have non-major histocompatibility of NK cells